Empresa Atossa Genetics Inc Nasdaq
Acciones
US04962H1005
Biotecnología e investigación médica
Precio de cierre
Otros sitios de cotización
|
||
- USD | - |
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Shu-Chih Chen
FOU | Founder | 62 | 01/12/08 |
Steven Quay
CEO | Chief Executive Officer | 73 | 01/12/08 |
Heather Rees
DFI | Director of Finance/CFO | - | 01/01/17 |
Arezoo Mirad
CTO | Chief Tech/Sci/R&D Officer | - | 04/12 |
Richard Graydon
CTO | Chief Tech/Sci/R&D Officer | - | 25/10/22 |
Delly Behen
ADM | Chief Administrative Officer | - | 01/01/14 |
Eric van Zanten
IRC | Investor Relations Contact | - | 07/12/22 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Steven Quay
CEO | Chief Executive Officer | 73 | 01/12/08 |
Director/Board Member | 66 | 01/03/14 | |
H. Remmel
BRD | Director/Board Member | 72 | 01/02/12 |
Shu-Chih Chen
FOU | Founder | 62 | 01/12/08 |
Stephen Galli
BRD | Director/Board Member | 77 | 01/07/11 |
Jonathan Finn
BRD | Director/Board Member | 50 | 08/11 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 127 077 462 | 125 684 004 ( 98,90 %) | 1 320 046 ( 1,039 %) | 98,90 % |
Acción B | 0 | 582 | 0 | 0 |
Información de la empresa
Atossa Therapeutics, Inc.
107 Spring Street
98104, Seattle
+206 588 0256
http://www.atossatherapeutics.comSector
Varia. 1 de ene. | Capi. | |
---|---|---|
+43,36 % | 54,63 mil M | |
-5,31 % | 39,92 mil M | |
+37,52 % | 38,82 mil M | |
+14,75 % | 26,86 mil M | |
-12,56 % | 26,22 mil M | |
-22,45 % | 18,78 mil M | |
+25,12 % | 12,21 mil M | |
+0,04 % | 12,16 mil M | |
+26,04 % | 11,94 mil M |
- Bolsa de valores
- Acciones
- Acción ATOS
- Acción
- Empresa Atossa Genetics Inc